The Axiolabs Tesamorelin 5 mg pack sits in the Best Anabolic Steroids catalogue as a lyophilised peptide vial for laboratory work. It is a modified form of growth hormone releasing hormone: the same hypothalamic signal, altered so that it survives longer in the bloodstream than the natural fragment, and mixed with bacteriostatic water before use.
This is the only peptide on the shelf with a licensed relative. An injectable version of the same molecule exists as a prescription medicine for excess visceral fat in patients with lipodystrophy, which gives it a real clinical record and, at the same time, creates the most common misunderstanding about the vial sold here: the research pack is not the approved product and carries no approved dose of its own.
Product Overview
Growth hormone release is a two step process: the hypothalamus sends a releasing signal, the pituitary answers with a pulse of growth hormone, and IGF-1 from the liver carries much of the downstream effect. A releasing hormone analog works upstream of the pituitary, so it raises endogenous growth hormone rather than injecting the hormone itself, and the body's own feedback still limits the response.
Two features describe the molecule. The first is duration: the general elimination half-life is quoted at 26-38 minutes, while the approved labelling for the stabilised form records an average nearer 8 minutes after a 1.4 mg subcutaneous dose. The second is the target that made it a medicine, visceral fat rather than muscle, with reductions documented over long daily use in a specific patient group rather than in healthy athletes. The GHRH family is prohibited at all times in sport.
Dosage Protocol
The only figures with a clinical basis are the doses of the licensed form, and they are quoted here as a medical reference rather than as instructions for the vial. They also make the arithmetic of a 5 mg pack obvious.
| Approved amounts | 2 mg daily for one formulation and 1.4 mg daily for the stabilised version, both by subcutaneous injection |
| Vial coverage | A 5 mg vial does not cover a week at either approved amount, which is a fact of arithmetic rather than of potency |
| Duration in clinic | Continuous daily use over long periods, not a short cycle |
| Research reference | No supplier cycle length for the research format is confirmed in the sources |
| Women | No separate female schedule appears in the reference material |
| Route | Subcutaneous, typically into the abdomen in the licensed protocol, with site rotation |
Anyone mixing this vial should decide the water volume first and write the resulting concentration on the label. Two millilitres in a 5 mg vial give 2.5 mg per ml, so 1 mg is 0.4 ml or 40 units on a U-100 syringe; that arithmetic matters more here than in most cards, because the clinical amounts are measured in milligrams rather than micrograms.
Suggested Protocols
Reference use is daily and long, which is the opposite of the short blocks typical elsewhere in the peptide category. The peptide is not stacked with other growth agents in a way that makes sense pharmacologically, since two releasing signals on the same pituitary simply compete for the same response.
When the goal is fat loss rather than growth hormone signalling, the parallel tools in this range are used in short diet phases instead: Clenbutaplex and T3 belong to weeks-long blocks rather than months-long daily routines. Any hormone cycle running alongside keeps its usual structure, and Arimiplex covers estradiol control, plus Tamoxiplex 20 or Clomiplex 50 for the recovery window of that cycle.
What to Expect
- Growth hormone and IGF-1 rise within hours. The signal appears quickly after an injection, but the effect on fat tissue is a matter of months.
- Visceral fat is the documented target. Reduction in deep abdominal fat was recorded under long daily use in a specific patient population, not in healthy users.
- The action is short. Eight minutes in the label of the stabilised form and 26-38 minutes generally, which is why the routine is one injection a day.
- Five milligrams is a small pack for this molecule. At approved amounts the vial lasts days, so realistic planning starts with how many vials a course needs.
- Blood sugar needs attention. Changes in glucose tolerance are part of the clinical profile and matter more to anyone with a family history of diabetes.
- Sport status is settled. The peptide falls inside the prohibited GHRH family, so it is unavailable to anyone tested.
Side Effects and Management
After the Course and Follow-Up
Post-cycle therapy has no role here: this peptide leaves the gonadal axis untouched. The follow-up that matters is metabolic: this molecule has a documented effect on glucose handling, and it is the reason monitoring is part of the clinical label rather than an optional extra.
The growth hormone side of the line, such as AxoTropin, and the ancillary items sit in the Axiolabs catalogue.
